Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip
by Zacks Equity Research
The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day.
The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem
Top Analyst Reports for Boeing, Abbott & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Abbott (ABT) and PayPal (PYPL).
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.
Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
by Zacks Equity Research
Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.
Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.
Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts
by Zacks Equity Research
Bruker's (BRKR) CALID and NANO groups hold promise.
Here's Why Investors Should Buy DexCom (DXCM) Stock Now
by Zacks Equity Research
Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.
Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.
Stryker Expands Acquisition Portfolio With Arrinex Buyout
by Zacks Equity Research
Stryker's (SYK) latest buyout is expected to boost its Neurotechnology & Spine business.
CVS Health Rides on Aetna Synergy, PBM Selling Season Modest
by Zacks Equity Research
With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.
Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Chemed's (CHE) Q4 revenues grow across key segments.
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
Why Is Abbott (ABT) Up 6% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $75.14 in the latest trading session, marking a -0.53% move from the prior day.
Medidata's (MDSO) Margins Under Pressure, Competition Rife
by Zacks Equity Research
Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.